Matches in Wikidata for { <http://www.wikidata.org/entity/Q67129826> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q67129826 description "clinical trial" @default.
- Q67129826 description "ensayu clínicu" @default.
- Q67129826 description "klinisch onderzoek" @default.
- Q67129826 description "клінічне випробування" @default.
- Q67129826 name "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 name "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 type Item @default.
- Q67129826 label "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 label "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 prefLabel "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 prefLabel "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer" @default.
- Q67129826 P1132 Q67129826-16470EF4-BF1F-45A4-826E-CD01F486B801 @default.
- Q67129826 P1476 Q67129826-D888CF32-C872-44AA-97F4-C84BD5A8F65B @default.
- Q67129826 P17 Q67129826-D7F86978-AC3C-4800-AC55-F3834E5A3EED @default.
- Q67129826 P1813 Q67129826-FDDECADB-487A-42C8-964A-7425A24E7628 @default.
- Q67129826 P2899 Q67129826-27321EC1-62DA-4C25-895F-3D92CA4E716B @default.
- Q67129826 P3098 Q67129826-4A21D831-9087-438D-A51C-0D7D7AE75EAD @default.
- Q67129826 P31 Q67129826-6D6C4DC5-138C-4700-A283-5717F8574B77 @default.
- Q67129826 P4844 Q67129826-779B4A58-C57A-4F55-A3C4-EFDD0A7B4DF5 @default.
- Q67129826 P4844 Q67129826-C81C3FD3-CACA-42A2-8632-AF671351AE64 @default.
- Q67129826 P580 Q67129826-CD4FB463-D6FF-49D3-B0B9-76B521F00CE8 @default.
- Q67129826 P582 Q67129826-9F68899E-536B-40A8-B3C0-DCBDD15308C7 @default.
- Q67129826 P8363 Q67129826-F17E2667-3974-4E63-B5E8-A8D512CA925C @default.
- Q67129826 P859 Q67129826-3A19911A-CDB4-4713-B1FB-2439278A3326 @default.
- Q67129826 P1132 "+113" @default.
- Q67129826 P1476 "Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria" @default.
- Q67129826 P17 Q29 @default.
- Q67129826 P1813 "Argo" @default.
- Q67129826 P2899 "+18" @default.
- Q67129826 P3098 "NCT02613208" @default.
- Q67129826 P31 Q30612 @default.
- Q67129826 P4844 Q413299 @default.
- Q67129826 P4844 Q423762 @default.
- Q67129826 P580 "2015-12-09T00:00:00Z" @default.
- Q67129826 P582 "2018-12-03T00:00:00Z" @default.
- Q67129826 P8363 Q818574 @default.
- Q67129826 P859 Q212646 @default.